Since Carl Woese’s discovery of archaea as a third domain of life, numerous archaeal species have been discovered, yet archaeal diversity is poorly characterized. Culturing archaea is complicated, but several queries about archaeal cell biology, evolution, physiology, and diversity need to be solved by culturing and culture-dependent techniques. Increasing interest in demand for innovative culturing methods has led to various technological and methodological advances. The current review explains frequent hurdles hindering uncultured archaea isolation and discusses features for more archaeal cultivation. This review also discusses successful strategies and available media for archaeal culturing, which might be helpful for future culturing practices.

The Ebola virus (EBOV) is a lethal pathogen causing hemorrhagic fever syndrome which remains a global health challenge. In the EBOV, two multifunctional proteins, VP35 and VP40, have significant roles in replication, virion assembly, and budding from the cell and have been identified as druggable targets. In this study, we employed in silico methods comprising molecular docking, molecular dynamic simulations, and pharmacological properties to identify prospective drugs for inhibiting VP35 and VP40 proteins from the myxobacterial bioactive natural product repertoire. Cystobactamid 934-2, Cystobactamid 919-1, and Cittilin A bound firmly to VP35. Meanwhile, 2-Hydroxysorangiadenosine, Enhypyrazinone B, and Sorangiadenosine showed strong binding to the matrix protein VP40. Molecular dynamic simulations revealed that, among these compounds, Cystobactamid 919-1 and 2-Hydroxysorangiadenosine had stable interactions with their respective targets. Similarly, molecular mechanics Poisson–Boltzmann surface area (MMPBSA) calculations indicated close-fitting receptor binding with VP35 or VP40. These two compounds also exhibited good pharmacological properties. In conclusion, we identified Cystobactamid 919-1 and 2-Hydroxysorangiadenosine as potential ligands for EBOV that target VP35 and VP40 proteins. These findings signify an essential step in vitro and in vivo to validate their potential for EBOV inhibition.

Extremophilic microorganisms offer an untapped potential for producing unique bioactive metabolites with therapeutic applications. In the current study, bacterial isolates were obtained from samples collected from Chamalang cave located in Kohlu District, Balochistan, Pakistan. The cave-derived isolate C1 (Rhodococcus jialingiae) exhibits prominent antibacterial activity against multidrug-resistant pathogens (MDR), including Escherichia coli, Staphylococcus aureus, and Micrococcus luteus. It also demonstrates substantial antioxidant activity, with 71% and 58.39% DPPH radical scavenging. Optimization of physicochemical conditions, such as media, pH, temperature, and nitrogen and carbon sources and concentrations substantially enhanced both biomass and metabolite yields. Optimal conditions comprise specialized media, a pH of 7, a temperature of 30 °C, peptone (1.0 g/L) as the nitrogen source, and glucose (0.5 g/L) as the carbon source. HPLC and QTOF-MS analyses uncovered numerous metabolites, including a phenolic compound, 2-[(E)-3-hydroxy-3-(4-methoxyphenyl) prop-2-enoyl]-4-methoxyphenolate, Streptolactam C, Puromycin, and a putative aromatic polyketide highlighting the C1 isolate chemical. Remarkably, one compound (C₁₄H₃₆N₇) demonstrated a special molecular profile, signifying structural novelty and warranting further characterization by techniques such as ¹H and ¹³C NMR. These findings highlight the biotechnological capacity of the C1 isolate as a source of novel antimicrobials and antioxidants, linking environmental adaptation to metabolic potential and supporting natural product discovery pipelines against antibiotic resistance.